Year: 2019
Type: article
Abstract: Significance There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB 2 R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2–CB 2 R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer.
Authors: Sandra Blasco-Benito, Estefanía Moreno, Marta Seijo-Vila, Isabel Tundidor, Clara Andradas, María M. Caffarel, Miriam Caro-Villalobos, Leyre Urigüen, Rebeca Diez-Alarcia, Gema Moreno-Bueno, Lucía Hernández, Luis Manso, Patricia Homar-Ruano, Peter J. McCormick, Lucka Bibic, Cristina Bernadó-Morales, Joaquín Arribas, Meritxell Canals, Vicent Casadó, Enric I. Canela, Manuel Guzmán, Eduardo Pérez-Gómez, Cristina Sánchez
Institutions: Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre, Hospital Universitario 12 De Octubre, Biomedical Research Networking Center on Neurodegenerative Diseases, Institut de Biomedicina de la Universitat de Barcelona, Universitat de Barcelona, Ikerbasque, Biogipuzkoa Health Research Institute, University of the Basque Country, Centro de Investigación Biomédica en Red de Salud Mental, Consejo Superior de Investigaciones Científicas, Hospital Universitario La Paz, Instituto de Investigaciones Biomédicas Sols-Morreale, Hospital La Paz Institute for Health Research, Centro de Investigación Biomédica en Red de Cáncer, MD Anderson Cancer Center Madrid, Universidad Autónoma de Madrid, University of East Anglia, Vall d'Hebron Institute of Oncology, Institució Catalana de Recerca i Estudis Avançats, Universitat Autònoma de Barcelona, Monash University, Instituto Ramón y Cajal de Investigación Sanitaria
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2912747255